U.S. Interactive Media and Services Stock News

Aardvark Therapeutics recently voluntarily paused its Phase 3 HERO trial of ARD-101 for hyperphagia in Prader-Willi Syndrome, and no longer expects to report topline data in the third quarter of 2026, with updated guidance now planned for the second quarter of 2026. The pause affects Aardvark’s lead asset in a rare disease setting where ARD-101 already holds both Orphan Drug and Rare Pediatric Disease designations from the FDA. We will now examine how the pause of the HERO Phase 3 trial for...

Hawaiian Electric Industries reported full-year 2025 revenue of US$3.09 billion, down slightly from US$3.22 billion in 2024, while swinging from a very large net loss to net income of US$123.12 million, or US$0.71 in basic and diluted earnings per share from continuing operations. The earnings rebound coincided with progress on Maui wildfire-related settlements, funded by insurance, and regulatory approval of a multi-year wildfire safety plan that supports both risk reduction and grid...

If you are wondering whether Enpro's current share price really reflects its underlying worth, this article walks through what the numbers actually say about value. Enpro's share price recently closed at US$264.05, with returns of 10.6% over 30 days, 20.5% year to date, 49.2% over 1 year, 155.4% over 3 years and 205.4% over 5 years. These figures may catch the eye of investors thinking about future risk and reward. Recent coverage around Enpro has focused on its role within the capital goods...

Why AES (AES) is on investors’ radar today AES (AES) is drawing attention after a mixed run in its share price, with a 1 day return of around 0.18% and a past 3 months total return of about 1.79%. Over the past year, the stock’s total return of roughly 34.25% contrasts with weaker multi year figures. At the same time, annual revenue of about US$12.1b and net income of roughly US$1.1b frame the current debate around valuation and business momentum. See our latest analysis for AES. That sharp 1...

Recently, GLOBALFOUNDRIES Inc. reported that short interest as a share of its freely tradable float fell 6.2%, to 12.7%, still well above the 4.53% average for peers. This decline suggests a shift in sentiment even as the company remains one of the more heavily shorted names among comparable semiconductor foundries. We’ll now explore how this reduction in short interest fits into GlobalFoundries’ broader investment narrative and evolving risk-reward profile. The future of work is here...

Public Service Enterprise Group (PEG) has drawn fresh attention as investors reassess its recent share performance, with the stock showing mixed short term moves but positive returns over the past month and past 3 months. See our latest analysis for Public Service Enterprise Group. The recent pullback, including a 1 day share price return of 1.82% decline to US$84.50 and a softer 7 day share price return of 2.10% decline, comes after steadier gains. The 30 day and 90 day share price returns...

UFP Technologies (NasdaqCM:UFPT) amended its manufacturing supply agreement with Intuitive Surgical. The amendment extends the term of the partnership between the two companies. Minimum volume commitments under the agreement were increased. A new program for additional products was added to the supply arrangement. For you as an investor, this centers on UFP Technologies' role as a specialized manufacturer for the medical device sector, supplying components and solutions to a leading global...

If you are wondering whether Modine Manufacturing's current share price actually lines up with its underlying worth, you are not alone. This article is going to focus squarely on what the numbers say about value. The stock last closed at US$238.50, with returns of 7.2% over 7 days, 29.2% over 30 days, 69.4% year to date and 209.2% over 1 year, while the 3 year return is very large and the 5 year return is around 15x. Recent news around Modine Manufacturing has largely centered on its role in...

Earnings, guidance and new buyback put Expro Group Holdings (XPRO) in focus Expro Group Holdings (XPRO) is back on investors’ radar after releasing fourth quarter and full year 2025 results, setting 2026 revenue guidance, and unveiling a new US$100 million share repurchase plan. The latest numbers give you a fresh look at how the business ended 2025. The guidance and buyback outline how management is thinking about the next phase. Here is what stands out from the announcement and how you...

Harrow (NasdaqGM:HROW) has introduced a new Direct-to-Prescriber PharmaPack offering focused on post-cataract surgery care. The PharmaPack kits provide access to FDA-approved ophthalmic products and are designed to be ordered directly by eye care providers. The launch aims to reduce reliance on off-label compounded formulations and support more standardized treatment protocols. For investors following ophthalmic therapeutics, Harrow sits at the intersection of branded eye care drugs and...

If you are wondering whether Truist Financial's current share price really lines up with its underlying worth, this article will walk through the key numbers that matter most. Over the short term, the stock has seen a 1.1% decline over 7 days and a 3.6% decline over 30 days. The longer term picture shows a 14.3% return over 1 year, 26.4% over 3 years, and 5.1% over 5 years from a last close of US$49.55. Recent market attention around large US banks has kept Truist Financial in focus,...

If you are wondering whether XPeng shares are pricing in too much hope or not enough, this article walks through what the current valuation really implies for investors. The stock recently closed at US$16.99, with returns of a 3.2% decline over 7 days, a 5.5% decline over 30 days, a 16.8% decline year to date, a 16.1% decline over 1 year and an 81.3% decline over 3 years, which gives a mixed picture of sentiment and risk. Recent headlines around XPeng have focused on broad themes such as...

This article examines whether PENN Entertainment at around US$14.85 appears attractively priced or potentially a value trap, by reviewing what the available numbers indicate about the stock. The share price has moved sharply in the short term, with a 22% return over the last 7 days and 15.7% over the last 30 days. This contrasts with a 28.5% decline over 1 year and a 51% decline over 3 years. Recent headlines have focused on PENN Entertainment's position in the US gaming and entertainment...

Palo Alto Investors LP opened a new position in Compass Therapeutics in the fourth quarter of 2025, acquiring 2,532,419 shares valued at about US$13.6 million, or roughly 1.89% of its assets under management. This move, alongside expectations for Compass’s bispecific antibody Tovecimig (CTX-009) in biliary tract cancer, highlights growing institutional interest in its oncology pipeline. Next, we will examine how rising institutional ownership, anchored by Palo Alto Investors’ new stake,...

If you are wondering whether Granite Construction's share price still offers value after a strong run, or if most of the upside is already reflected, this article breaks down what the current market price might be implying. The stock most recently closed at US$133.84, with a 7 day return of a 0.7% decline, a 30 day return of 10.8%, a year to date return of 12.8%, a 1 year return of 65.3%, a 3 year return that is very large, and a 5 year return that is very large. Recent price moves sit...

If you are wondering whether SPS Commerce shares are now priced attractively or still look expensive, you are not alone. This review is aimed squarely at that question. The stock most recently closed at US$58.41, with returns of 7.7% over the past week, a 34.6% decline over 30 days, a 33.6% decline year to date, and a 55.8% decline over 1 year. The 3 year and 5 year returns stand at 61.2% and 41.1% declines respectively. Recent coverage around SPS Commerce has focused on keeping investors...

Veracyte (VCYT) has drawn attention after recent share price moves, with the stock showing mixed returns across different time frames, including declines over the past month and past 3 months alongside a positive 1 year total return. See our latest analysis for Veracyte. At a share price of US$36.01, Veracyte’s recent performance reflects fading short term momentum, with a 30 day share price return of 5.44% and a 90 day share price return of a 21.99% decline, set against a 1 year total...

In late February 2026, Virtu Financial reported Q4 2025 results showing its highest quarterly adjusted net income since early 2021, supported by elevated market volatility and strong trading volumes across both Market Making and Execution Services. An interesting angle for investors is Virtu’s plan to channel this momentum into higher trading capital, upgraded infrastructure, and moves into emerging areas such as prediction markets and crypto. We’ll now explore how this stronger quarter,...

Zenas BioPharma has recently been highlighted for moving from a pre-revenue stage toward commercialization of its lead antibody therapy obexelimab, targeting IgG4-Related Disease, an area with no approved treatments. An interesting aspect of this story is Zenas’ reported cash position of about US$270,000,000 entering 2026, which supports its plans to expand a pipeline focused on B‑cell‑mediated autoimmune diseases while advancing obexelimab toward market. Against this backdrop, we’ll examine...

If you are looking at Fluor and wondering whether the current share price gives you good value, you are not alone. This article focuses squarely on what you might be paying for compared to what you are getting. After closing at US$50.91, the stock has seen a 1.4% decline over the last 7 days, a 10.2% gain over 30 days, a 22.1% return year to date, and a 37.9% return over the past year, which may change how investors think about both upside and risk. Recent attention on Fluor has been driven...

Advance Auto Parts (AAP) is back on many investors’ screens after its share price returned 37% year to date, even though 3 year and 5 year total returns remain deeply negative. See our latest analysis for Advance Auto Parts. That 36.98% year to date share price return and 53.92% 1 year total shareholder return suggest improving sentiment around Advance Auto Parts, even though the 3 and 5 year total shareholder returns remain sharply negative. If this rebound has you thinking about what else...

Exzeo Group has entered into a new partnership with Tokio Marine Highland to distribute TMH2O residential flood insurance. The collaboration expands Exzeo’s property insurance offerings and supports its ambitions as a multi-line, technology driven platform. For investors tracking NYSE:XZO, this announcement comes as the stock trades at $16.1, with a 3.7% gain over the past week and a 20.8% decline over the past month. Year to date, shares show a 29.3% decline, so this move may stand out as...

If you are wondering whether First Solar's current share price reflects its true worth, this article will walk through how that value stacks up against a range of valuation checks. The stock last closed at US$199.86, with a 17.5% decline over the past 7 days and an 11.4% decline over the past 30 days, although the 1 year return sits at 56.6% and the 5 year return at 179.7%. These moves come as First Solar continues to sit in the spotlight of the wider solar and semiconductor industry, with...

Event overview and recent share performance Charles River Laboratories International (CRL) has drawn investor attention after recent share price moves, with the stock flat over the past day, up about 9% over the past week, but showing a 15% decline over the past month. Over the past 3 months, Charles River has posted a small positive total return, while year to date the stock is down about 12%. Over the past year, it has delivered roughly 9% total return, set against weaker 3 year and 5 year...